Unclaimed brand
At DAMIAN, we believe that the true value of an idea lies in its real-world implementation. Our singular pursuit is to find therapeutic solutions for patients, matching distinct drug pharmacologies to well-characterized disease pathways. Putting compassion into action, DAMIAN is on a purposeful expedition to bring first-of-a-kind solutions for patients with aldosterone-dependent conditions. DAMIAN is a privately-held pharmaceutical company incorporated in Switzerland in 2015. Led by 3 industry veterans with 75+ years of experience developing innovative life-saving drugs, we execute our projects with the support of leading disease experts, clinical advisors, and established contract manufacturing and research organizations across the globe. We apply our deep expertise to our first indication, Primary Aldosteronism, which has a well-explained causality and a direct therapeutic target. DAMIAN is creating new solutions through our targeted drug, dexfadrostat phosphate (DP13), and diagnostic tracer, DP14. With perseverance and conviction, we endeavor to find therapeutic solutions wherever they exist, for the people who need them.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#AF6D3D
Brown Rust
175, 109, 61
25, 48, 46
0, 38, 65, 31
#48C3D1
Shakespeare
72, 195, 209
186, 60, 55
66, 7, 0, 18
#196583
Blumine
25, 101, 131
197, 68, 31
81, 23, 0, 49
DAMIAN Pharma is a privately held pharmaceutical company incorporated in Switzerland in 2015. Led by three industry veterans with more than 75 years of combined experience developing innovative medicines, the company works with disease experts, clinical advisors, and contract research and manufacturing organizations worldwide. Its focus is developing therapeutic solutions for aldosterone-dependent conditions, beginning with Primary Aldosteronism (PA), an endocrine disorder in which excess aldosterone disrupts the body’s regulation of water and electrolytes.
DAMIAN’s development program combines a targeted investigational drug, dexfadrostat phosphate (DP13), with DP14, a diagnostic tracer intended for PET imaging of aldosterone-producing adenomas. The company aims to match these products to the underlying disease pathways and improve options for people with PA, for whom it describes a lack of targeted therapy. DP13 completed Phase I and was evaluated in a Phase II study. DAMIAN states that, together with DP14, the therapy may help medically control PA and offer an alternative to surgery. The company also provides investor information and news about its research and development progress.
Company type
Privately Held
Year founded
2015
Company size
2-10 employees
The DAMIAN Pharma name, logos and brand assets are trademarks of DAMIAN Pharma and its affiliates. Brandfetch isn't affiliated with or endorsed by DAMIAN Pharma. Their use is subject to DAMIAN Pharma's brand guidelines.
